Video on how to take a microbiome sample with Sequential's microbiome testing kit.

Who We Help Your end-to-end clinical testing partner. Dermocosmetics & Personal Care We help innovative dermocosmetic and personal care brands generate clinical-grade evidence and multi-omics insight, revealing not just efficacy, but true mechanisms of action and competitive positioning. Find out more Derm Pharma Therapeutics As a specialised CRO for dermatological therapeutics, we go beyond traditional study execution, delivering biomarker-driven clinical evaluation through validated assays, condition-specific expertise, and rigorous, reproducible methodologies. Find out more Clinical Research Organisations We partner with CROs to provide advanced microbiome, genomic, and biomarker analysis—supporting complex study requirements without compromising timelines, quality, or client expectations. Find out more Ingredient Manufacturers We help ingredient manufacturers generate robust, clinically relevant evidence by testing actives within controlled formulations, delivering clear insight into biological impact and optimal performance. Find out more

Understand how your product changes microbial communities. Composition, diversity and target microorganisms profiled by sequencing and quantitative methods. Microbiome Biomarker Analyses We provide end-to-end clinical microbiome research and testing platform. Supported by a rapidly expanding, industry-leading database of over 50,000+ human samples, our comprehensive services span biophysical product assessments, full study recruitment, and collaborative publishing to drive science-backed solutions. Start Your Study Today Our Layers of Analysis Smart Probes™ (qPCR) Investigate the absolute quantification of key microbes in any sample down to sub-species. Assess how a product impacts the most significant bacteria in a sample. Bacteria Profiling (16s) Investigate all present bacteria in any given sample. Understand how a product impacts the skin's bacterial community. Microbial Gene Expression Uncover how genes are activated in response to lifestyle, environment, & treatments. The effect of product on skin-related microbial gene expression. Fungal Profiling (ITS) Investigate all present fungi in any given sample. Understand how a product impacts the skin's fungal community. Whole Microbial Profiling Investigate all present fungi in any given sample. Understand how a product impacts the skin's bacteria, fungal and viral communities Our Test Areas Skin Test skin formulations, actives and finished products from cleansers, serums and moisturisers to SPFs and treatments. Sequential Smart Probes™ Click on a targeted panel to discover more. Why Sequential? Claim Ready Science Molecular evidence for claims broken down into market positioning insights. Real World Testing Studies done on real people from our global, expansive database. End-to-End Platform We’ll handle everything for you from study design and recruitment to market advice. Flexible & Scalable In-lab or remote studies made possible via our proprietary Sequential Skin Patch™.

At Sequential we take your privacy seriously. For a full breakdown, please read through our policy on how we use your information for microbiome product testing. Privacy Policy Last updated: Jul 28, 2026 Sequential Skin Ltd is committed to using personal information lawfully, fairly and transparently. This Privacy Policy explains how we use personal information in connection with sequential.bio (the Site), general business communications, marketing, supplier and customer relationships, and recruitment. Separate privacy information may apply to a research study, clinical or consumer testing programme, sample analysis, app, portal, customer project or employee relationship. If a specific notice is provided for one of those activities, that notice applies to that activity and takes priority if there is any inconsistency. 1. Who we are and how to contact us Sequential Skin Ltd is a company registered in England and Wales under company number 12547483. Our registered office and postal address is Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom. For the processing described in this policy, Sequential Skin Ltd is generally the controller. In some customer-sponsored studies or projects, we may act only as a processor on another organisation's instructions; in that case, the relevant controller's privacy notice explains how your information is used. Privacy enquiries and rights requests: team@sequential.bio 2. Scope of this policy This policy applies to visitors to the Site, people who contact us, newsletter subscribers, prospective and current business contacts, customer and supplier representatives, job applicants, and other individuals whose information we process for our own business purposes. The Site is not directed at children. A study involving a child or young person will use a specific recruitment, consent and privacy process appropriate to that study. 3. Personal information we collect Identity and contact information. Name, title, employer, role, postal address, email address, telephone number and account identifiers. Business and relationship information. Organisation, sector, professional interests, correspondence, meeting notes, enquiries, proposals, contract details and relationship history. Marketing information. Subscription choices, preferred topics and channels, consent records, objections, suppression records and engagement with communications. Technical and usage information. IP address, browser and device information, time zone, approximate location derived from IP, security logs, identifiers and information about how the Site and emails are used. Account and security information. Login or authentication records, permissions, activity logs and information used to prevent fraud, abuse or unauthorised access. Recruitment information. CV, qualifications, employment history, work eligibility, application responses, interview notes, references and information reasonably required to assess an application. Other information you provide. Information included in forms, messages, documents, feedback or support requests. 4. Special category and study information Please do not send health, genetic, biometric or other special category information through a general website or contact form unless we specifically ask for it and explain why it is needed. If you apply for or take part in a research study, clinical study, consumer testing programme or sample-based service, Sequential or the relevant sponsor may process health, genetic, biometric, microbiome or other sensitive information. A study- or service-specific notice will identify the controller and explain the purpose, lawful basis, applicable special-category condition, safeguards, retention and sharing. Study participation and consent to take part in research are separate from consent used as a data-protection lawful basis. 5. How we obtain information We obtain information directly from you when you use the Site, contact us, subscribe, meet with us, enter a business relationship or apply for a role. We also obtain information automatically from devices and services, subject to cookie choices. We may obtain business contact information from your employer or colleagues, event organisers, professional networks, referral partners, publicly available professional sources, service providers, recruitment agencies or customers and partners. When information is obtained from another source, we provide privacy information as required by law unless an exception applies. 6. Why we use information and our lawful bases Operate and secure the Site. To deliver pages and requested features, maintain availability, prevent misuse, troubleshoot and protect systems. We rely on legitimate interests in operating a secure and effective website, legal obligations where applicable, and consent for optional technologies where required. Respond to enquiries and develop relationships. To communicate, arrange meetings, understand requirements, prepare proposals and manage prospective or current customer, supplier and partner relationships. We rely on steps requested before a contract, performance of a contract, and legitimate interests in running and developing our business. Provide and administer contracted services. To onboard organisations, administer accounts, communicate about delivery, invoice, maintain records and enforce agreements. We rely on contract where you are a contracting individual, legitimate interests where the contract is with your organisation, and legal obligations. Marketing and events. To send newsletters, invitations and relevant business communications, measure engagement and manage preferences. We rely on consent where required by electronic-marketing law and otherwise on legitimate interests, subject to your right to object. Every direct marketing message will offer an appropriate way to opt out. Improve services and understand use. To analyse feedback and, where permitted, Site usage, identify trends and improve content, services and user experience. We rely on legitimate interests and on consent for cookies or similar technologies where required. Recruit people. To manage applications, assess suitability, communicate with candidates, check eligibility, take steps before an employment contract and protect legal rights. We rely on steps before contract, legal obligations and legitimate interests in recruitment and defending claims. Any special category information is used only under an applicable legal condition. Meet legal and compliance obligations. To keep records, respond to rights requests and complaints, comply with tax, accounting, corporate, regulatory or court requirements, and establish, exercise or defend legal claims. We rely on legal obligations and legitimate interests. Corporate transactions. To evaluate or complete an investment, financing, restructuring, sale, merger or transfer, with appropriate confidentiality and data-protection safeguards. We rely on legitimate interests in managing our business and assets and legal obligations where applicable. Where we rely on legitimate interests, we consider the necessity of the processing and balance our interests against the impact on your rights and freedoms. You may ask for more information about that assessment. 7. Marketing choices You can unsubscribe from marketing emails using the link in the message or by contacting us. We may continue to send service, security, legal or relationship communications that are not direct marketing. We keep a minimal suppression record after an opt-out so that we can respect your choice. Electronic-marketing rules vary by recipient type. We obtain consent where required and do not use pre-ticked boxes or treat silence as consent. Business contacts can object to direct marketing at any time. 8. Cookies and similar technologies Our Cookie Policy explains the technologies used on the Site, when consent is required, and how to change your choices. Optional technologies are controlled through Cookie Settings. Cookie Policy: sequential.bio/cookiepolicy 9. When we share information We share personal information only where necessary and subject to appropriate safeguards. Recipients may include: hosting, cloud, communications, security, analytics, customer-relationship, marketing and other technology providers; professional advisers, auditors, insurers, banks and payment providers; customers, suppliers, research partners, laboratories, clinical research organisations or study sponsors where relevant and explained in the applicable relationship or specific notice; recruitment agencies, screening providers and referees in connection with applications; regulators, courts, law enforcement and public authorities where disclosure is required or permitted by law; and prospective buyers, investors, lenders or counterparties and their advisers in connection with a corporate transaction, subject to confidentiality and appropriate controls. Service providers acting as processors may use information only on our documented instructions, must protect it and must not use it for their own unrelated purposes. Where another recipient acts as an independent controller, its own privacy notice also applies. 10. International transfers Some providers or recipients may be located outside the United Kingdom, or may allow access from another country. When we make a restricted transfer, we use a lawful transfer mechanism, such as UK adequacy regulations or appropriate safeguards including the UK International Data Transfer Agreement or the UK Addendum to approved standard contractual clauses. Where required, we complete a data protection test or transfer risk assessment and apply supplementary safeguards. We use a legal exception only where the law permits and the conditions are met. You may contact us for more information about the transfer mechanism relevant to your information, subject to lawful confidentiality restrictions. 11. How long we keep information We keep personal information only for as long as reasonably necessary for the purpose for which it was collected, including legal, accounting, reporting, security and dispute-resolution requirements. We use a documented retention approach that considers the amount, nature and sensitivity of the information, risk of harm, purpose, whether the purpose can be achieved another way, and applicable limitation or regulatory periods. Enquiries and business contacts. For the active relationship and a reasonable follow-up period, then deletion or minimisation unless records are needed for a contract, legal obligation or claim. Contracts and transaction records. For the contract and the relevant legal, tax, accounting and limitation periods after it ends. Marketing. Until you opt out or the information is no longer needed under our review rules; a minimal suppression record may be kept longer to respect the opt-out. Recruitment. For the recruitment exercise and a reasonable period to manage queries or claims, or longer with permission where we wish to consider you for future roles. Security and technical logs. For a proportionate period based on security, troubleshooting and legal needs. Studies and sensitive processing. As stated in the applicable study, service or participant notice and relevant protocol or contract. 12. Security We use appropriate technical and organisational measures designed to protect personal information against accidental or unlawful destruction, loss, alteration, disclosure or access. Measures are selected according to risk and may include access controls, confidentiality obligations, encryption in transit or at rest where appropriate, backups, monitoring, supplier due diligence and incident procedures. No internet transmission or storage system can be guaranteed completely secure. 13. Your data protection rights Depending on the circumstances, you may have the right to: be informed about how your personal information is used; request access to your personal information; request correction of inaccurate or incomplete information; request erasure of information where there is no lawful reason to continue using it; request restriction of processing in specified circumstances; object to processing based on legitimate interests and object at any time to direct marketing; receive or transfer certain information in a structured, commonly used and machine-readable format; withdraw consent at any time where processing is based on consent, without affecting earlier lawful processing; and ask for safeguards where a significant decision is made solely by automated processing, where applicable. These rights are not absolute and exemptions may apply. We may ask for information reasonably needed to confirm identity or clarify a request. We normally respond without undue delay and within the period required by law. A fee is not normally charged, but the law permits a reasonable fee or refusal in limited cases, such as manifestly unfounded or excessive requests. 14. Automated decision-making We do not currently use personal information collected through the Site to make decisions based solely on automated processing that produce legal or similarly significant effects. If that changes, we will provide specific information about the logic, significance, consequences and safeguards, including how to obtain human intervention and contest a decision. 15. Data protection complaints If you believe we have used your personal information unlawfully, contact us at team@sequential.bio or by post at Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom and mark the correspondence "Data protection complaint". We will help you make the complaint, acknowledge it within 30 days, investigate it, keep you appropriately informed and tell you the outcome without undue delay. You may also complain to the Information Commissioner's Office, the United Kingdom supervisory authority. We would appreciate the opportunity to address your concern first, but this does not affect your right to contact the ICO. ICO complaints information: ico.org.uk/make-a-complaint 16. Third-party links The Site may contain links, plug-ins or embedded content provided by third parties. Those organisations may collect information under their own privacy notices. We do not control their independent processing and encourage you to review their notices. 17. Changes to this policy We review this policy and may update it when our activities or legal requirements change. The date at the top shows the latest revision. If a change materially affects how we use information already collected, we will take reasonable steps to bring it to the attention of affected people and obtain consent where required. Contact us Questions about this Privacy Policy, your rights or a data protection complaint may be sent to: Sequential Skin Ltd (company number 12547483) Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom Email: team@sequential.bio

Malodor, or body odor, affects millions of people globally, with studies suggesting that up to 90% of individuals experience some form of body odor during their lifetime, especially in areas such as the underarms, feet, and groin (American Society for Microbiology). TARGETED SKIN PANEL Malodor Targeted Panel 23 Smart Probes ™ Malodor Panel Validated targets: Corynebacterium species, Staphylococcus hominis, Cutibactrium acnes species Absolute Quantification End-to-end Service Qet a Quote Unlock the Secrets of Malodor with Sequential's Cutting-Edge Microbiome Testing Why Microbiome Testing for Malodor? Malodor, or body odor, affects millions of people globally, with studies suggesting that up to 90% of individuals experience some form of body odor during their lifetime, especially in areas such as the underarms, feet, and groin (American Society for Microbiology). This issue arises primarily due to interactions between sweat and the skin’s microbiome, where certain bacteria, like Corynebacterium and Staphylococcus , break down sweat molecules into odorous compounds. The composition of a person’s microbiome greatly influences the severity and type of body odor they experience, which highlights the need for microbiome-focused deodorant formulations. In vivo testing is crucial for deodorants because it allows scientists to see how the product affects both sweat production and the microbiome in real-world conditions. Without proper testing, deodorants might mask odors temporarily but disrupt the natural microbial balance, leading to skin irritation or increased malodour over time. By ensuring deodorants maintain a healthy microbiome, brands can create more effective, long-lasting solutions for body odor. Sequential is leading the way in microbiome testing for the industry. With a specialized focus on skin conditions, we have developed an innovative solution tailored to help you understand the root causes of malodor at the microbial level. Our proprietary sequencing panel is designed specifically to offer in-depth analysis of malodor-associated microbiota, giving you the tools to transform skincare solutions. Customized Analysis Tailored insights specific to malodor, allowing your R&D team to develop more personalized and effective products. Actionable Data Leverage detailed reports to guide formulation decisions and validate product efficacy with precision. Product Innovation New deoderants or enhancing existing lines, our data helps you create targeted solutions with proven results. Precision Sequencing Target specific microbial communities associated with malodor. Smart Probe s ™ Our dedicated team of scientists has developed a groundbreaking method for evaluating microbes through our Smart Probes™, a proprietary panel featuring 23 key microbes specifically identified as having the greatest impact on skin health, particularly in relation to malodor. To further investigate the complex relationship between body odor and the skin microbiome, we employ qPCR technology. This advanced technique enables us to precisely measure microbial populations on the skin, providing deeper insights into how imbalances in the microbiome contribute to malodor, such as the activity of bacteria like Corynebacterium and Staphylococcus . By carefully analyzing how deodorant and skincare products interact with odor-causing microbes, companies can develop solutions that not only target and reduce malodor but also support a healthy, balanced skin microbiome, ensuring long-lasting freshness and overall skin health. Malodor Panel Targets Corynebacterium species These bacteria are known to break down sweat into fatty acids and other compounds that contribute to body odor. They are particularly prevalent in areas like the armpits. Ågren MS, Ghathian KSA, Frederiksen AKS, Bjerrum MJ, Calum H, Danielsen PL, Menon J, Hædersdal M, Jorgensen LN. Zinc Oxide Inhibits Axillary Colonization by Members of the Genus Corynebacterium and Attenuates Self-perceived Malodour: A Randomized, Double-blind, Placebo-controlled Trial. Acta Derm Venereol. 2020 May 28;100(10):adv00145. doi: 10.2340/00015555-3499. PMID: 32399578; PMCID: PMC9137363. Staphylococcus hominis This bacterium is involved in the breakdown of sweat and the production of odor-causing compounds. It is commonly found in areas with high sweat gland activity. Lam, T.H., Verzotto, D., Brahma, P. et al. Understanding the microbial basis of body odor in pre-pubescent children and teenagers. Microbiome 6, 213 (2018). https://doi.org/10.1186/s40168-018-0588-z Cutibacterium acnes species Although better known for its role in acne, this bacterium also contributes to body odor by metabolizing sweat and producing odoriferous substances. Coenye T, Spittaels KJ, Achermann Y. The role of biofilm formation in the pathogenesis and antimicrobial susceptibility of Cutibacteriumacnes. Biofilm. 2021 Dec 9;4:100063. doi: 10.1016/j.bioflm.2021.100063. PMID: 34950868; PMCID: PMC8671523. Industry Leader in Absolute Quantification Sequential’s Smart Probe ™ qPCR approach to microbiome analysis can resolve species and subspecies, giving statistically significant findings between skin conditions on in vivo human samples, compared to conventional sequencing approaches. Relevant Research Unveiling the Microbial Truth: The Unpleasant Reality of Scalp Malodour Don't Sweat It: How Deodorant Disrupts Your Underarm Microbiome Read More Articles

Thank you for getting in touch! We will review your query and get back to you within 1-2 business days.

Seeking formulation support? Embark on the journey to your next best-selling product with our assistance. Let's collaborate and create success together! Create Your Next Best-Selling Formulation A well-designed formulation takes into account the diverse and delicate ecosystem of the microbiome. By incorporating ingredients that promote a harmonious relationship with the microbiota, such as prebiotics and postbiotics, a product can positively impact the microbial diversity and balance on the body. Having collected over 20,000+ human skin microbiome samples through in vivo clinical research, we can help you take your product from conception to completion. Consultation Book a consultation to start creating your microbiome supporting formulation. Whether you need help starting out or are already in the midst of your process, we can support you. INCI List Examination Have an INCI list and are unsure if it will be a formula? No need to look further, we will gladly look through your proposed INCI list and revert back with feedback. Co-Develop Let us be your Chief Science Officer, or your scientific advisory, and leverage our dataset for the co-development of products that suit your demographic and application. SKINCARE FORMULATIONS Regular to Atopic Skin, Start Formulating Today! What Contributes to a Microbiome Supporting Formulation? When creating a product that "maintains the microbiome", it is crucial to understand that every ingredient used is important. Hero ingredient-led philosophy cannot be applied in the formulation process as it is the blend of each ingredient that will create a product to support and improve the balance of the skin microbiome. Fermented ingredients (postbiotics) and those that act as food for microbes (prebiotics) are also known to have a positive impact on formulations when paired with the right preservative systems, surfactants, emollients, etc. It is still rare to find live bacteria (probiotics) in formulations, however, if encapsulated correctly, it could show improvement in the microbiome balance. Prebiotics Prebiotics beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria on the skin, and thus improves host health. Prebiotics act as food for the microbes on the skin, and allow good bacteria to grow and thrive. Probiotics Probiotics are living microorganisms that confer benefit to the host when applied to the body. Because probiotics are live bacteria, it is incredibly difficult to preserve and put into skincare products (especially when skincare contains preservatives). In fact, some products on the market that say they use probiotics, are actually using prebiotics or postbiotics. Postbiotics Postbiotics are the byproduct of fermented live bacteria (probiotics) or inactivated microorganisms. The process of fermentation releases nutrients inside of the bacteria and holds concentrated and nourishing skin health benefits that help to balance the skin microbiome. INGREDIENTS FROM MICROBIAL ORIGIN No INTENDED TO BE UTILISED BY THE HUMAN MICROBIOTA? No Yes Yes ARE THEY VIABLE? No Yes ORIGIN VIABILITY FUNCTION ORDINARY INGREDIENT ORDINARY INGREDIENT WITH PREBIOTIC FUNCTION INTENDED TO BE UTILISED BY THE HUMAN MICROBIOTA? PROBIOTIC INGREDIENT No POSTBIOTIC INGREDIENT Yes POSTBIOTIC INGREDIENT WITH PREBIOTIC FUNCTION Our Leading Expert & Skincare Director Pétronille Houdart A pharmacist by training, Pétronille specialized in dermo pharmacy and cosmetology. She has garnered extensive experience in the formulation of cosmetic products and is passionate about skincare. She started her career working for a private-label contract manufacturer that focused on custom cosmetic formulations for clients ranging from big brands to private dermatologist products. She has previously created a high-performance customisable formulation brand and is vocal about bespoke and innovative cosmetic formulations. Request a Consultation Ashfi Rahman, Co-founder at HonestStory "Sequential gave us completely essential consulting work on microbiome skincare formulations. They are the only company out there that combines their knowledge of microbiome testing with formulation expertise, and we're very happy to be working with them to develop the first microbiome skincare in India." FAQ What is Sequential's testing platform? Sequential has developed the gold standard test for microbiome-friendly products, in vivo (in, or on, humans). Finally, we can give some certainty about if a product is truly affecting the microbiome. We offer a complete end-to-end solution to support microbiome-friendly claims. From consultancy and study design to our proprietary microbiome testing kits. We analyse, interpret and report our findings to meet your needs. Why is it necessary to test the microbiome in vivo? What type of sequencing technology does Sequential use for analysis? Does Sequential offer claims certification for tested products?

Atopic dermatitis (AD), a chronic inflammatory skin condition, affects around 31.6 million people in the U.S., with 15-20% of children globally and 7.3% of U.S. adults experiencing the condition. TARGETED SKIN PANEL Atopic Dermatitis Targeted Panel 23 Smart Probes ™ Atopic Dermatitis Panel Validated targets: Staphylococcus aureus, Malassezia spp, Staphylococcus epidermidis Absolute Quantification End-to-end Service Qet a Quote Atopic Dermatitis Study with Sequential's Cutting-Edge Microbiome Testing Why Microbiome Testing for Atopic Dermatitis? Atopic dermatitis (AD), a chronic inflammatory skin condition, affects around 31.6 million people in the U.S., with 15-20% of children globally and 7.3% of U.S. adults experiencing the condition (National Eczema Association). AD often results from a combination of genetic predisposition and environmental triggers, such as irritants in cosmetic products. Disruptions to the skin’s microbiome play a significant role in the disease's development and severity. Imbalances in beneficial and harmful microbes can exacerbate AD, highlighting the importance of targeted treatments. In vivo testing for products aimed at managing AD is essential because it allows researchers to understand how formulations impact both the skin barrier and microbiome in real-world conditions. Properly tested products can help reduce irritation and avoid worsening symptoms, offering a science-backed approach to skincare for those with AD. Sequential is leading the way in microbiome testing for the industry. With a specialized focus on skin conditions, we have developed an innovative solution tailored to help you understand the root causes of AD at the microbial level. Our proprietary sequencing panel is designed specifically to offer in-depth analysis of AD-associated microbiota, giving you the tools to transform skincare solutions. Customized Analysis Tailored insights specific to AD-prone skin, allowing your R&D team to develop more personalized and effective products. Actionable Data Leverage detailed reports to guide formulation decisions and validate product efficacy with precision. Product Innovation New AD treatments or enhancing existing lines, our data helps you create targeted solutions with proven results. Precision Sequencing Target specific microbial communities associated with AD development and severity. Smart Probe s ™ Our dedicated team of scientists has developed a revolutionary method for evaluating microbes through our Smart Probes™. This proprietary panel includes 23 key microbes that we have specifically identified as having the most significant impact on skin health. To further understand the intricate relationship between atopic dermatitis (AD) and the skin microbiome, we use qPCR technology. This advanced technique allows us to precisely quantify microbial populations on the skin, providing deeper insights into how AD affects the microbiome. By closely monitoring how products interact with both beneficial and harmful microbes, companies can create solutions for AD but also restore a healthy balance to the skin’s ecosystem. Atopic Dermatitis Panel Targets Staphylococcus aureus This bacterium is frequently found in higher numbers on the skin of individuals with atopic dermatitis. It can exacerbate inflammation and contribute to skin barrier disruption. Malassezia spp This genus of yeast, which is part of the normal skin flora, can become overgrown in individuals with atopic dermatitis, potentially aggravating symptoms. Staphylococcus epidermidis While generally considered a commensal organism, imbalances in its population, along with other microbes, can influence the skin's health and contribute to atopic dermatitis symptoms. Industry Leader in Absolute Quantification Sequential’s Smart Probe ™ qPCR approach to microbiome analysis can resolve species and subspecies, giving statistically significant findings between skin conditions on in vivo human samples, compared to conventional sequencing approaches. Relevant Research Revolutionising Eczema Care: The Promise of Live Biotherapeutic Products AOB for AD: Ammonium-oxidising Bacteria as an Innovative Approach to Managing Atopic Dermatitis Answers for Atopic Dermatitis and Allergies: What is the Role of the Skin Bacteriome? Read More Articles

The Biome Mask has been created with the goal of maintaining the microbiome while targeting concerns such as skin dehydration and sensitivity. Introducing the Biome Mask™ Sequential Skin is proud to announce its biodegradable Biome Mask™ line designed to balance the skin microbiome and make your skin healthier. The Biome Mask™ line has five formulas to target five skin traits. Each is infused with serums that target specific concerns and uses prebiotics and postbiotics to balance the skin's microbiome. All masks have been tested in vivo. Made for all skin types Our formula, your benefits Semi-gel Tencel™ Versatile, soft & pleasant to the skin Eco-friendly Material Better for you and the planet 100% Cellulose Cellulose is the most abundant natural organic compound on Earth Remarkable Moisture Retention For long lasting benefits Click Here to see a Full List of our Ingredients How They Work Prebiotics Prebiotics beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria on the skin, and thus improves host health. Feed your skin microbiome! Prebiotics act as good for the microbes on the skin, and allow good bacteria to grow and thrive. Probiotics Probiotics are living microorganisms that confer benefit to the host when applied to the body. Because probiotics are live bacteria, it is incredibly difficult to preserve and put into skincare products (especially when skincare contains preservatives). In fact, some products on the market that say they use probiotics, are actually using prebiotics or postbiotics. Postbiotics Postbiotics are the byproduct of fermented live bacteria (probiotics) or inactivated microorganisms. The process of fermentation releases nutrients inside of the bacteria and holds concentrated and nourishing skin health benefits that help to balance the skin microbiome. INGREDIENTS FROM MICROBIAL ORIGIN No INTENDED TO BE UTILISED BY THE HUMAN MICROBIOTA? No Yes Yes ARE THEY VIABLE? No Yes ORIGIN VIABILITY FUNCTION ORDINARY INGREDIENT ORDINARY INGREDIENT WITH PREBIOTIC FUNCTION INTENDED TO BE UTILISED BY THE HUMAN MICROBIOTA? PROBIOTIC INGREDIENT No Yes POSTBIOTIC INGREDIENT POSTBIOTIC INGREDIENT WITH PREBIOTIC FUNCTION Also available in a box of 5 Biome Masks™ Interested? Frequently asked questions What is the Biome Mask™ made from? We provide Semi-Gel Tencel masks that are made of 100% cellulose material and are eco-friendly. Each one of our masks is infused with serums that target your specific skin care needs. Semi-gel Tencel masks have the remarkable ability to retain moisture, making them better than cotton sheet masks and feel softer on the skin. What ingredients are used in the Biome Mask™? Are the masks biodegradable? What is the shelf life of the masks? What is the purpose of using a sheet mask? How long should the mask be left on the face?

Rosacea is a chronic skin condition affecting an estimated 16 million Americans and millions more worldwide, primarily adults over 30 (National Rosacea Society). TARGETED SKIN PANEL Rosacea Targeted Panel 23 Smart Probes ™ Rosacea Panel Validated targets: Demodex mites, Bacillus oleronius, Corynebacterium kroppenstedtii Absolute Quantification End-to-end Service Qet a Quote Unlock the Secrets of Rosacea with Sequential's Cutting-Edge Microbiome Testing Why Microbiome Testing for Rosacea? Rosacea is a chronic skin condition affecting an estimated 16 million Americans and millions more worldwide, primarily adults over 30 (National Rosacea Society). Characterized by redness, visible blood vessels, and inflammation, rosacea can significantly impact an individual’s quality of life. Research suggests that the skin microbiome plays a crucial role in the development and severity of rosacea. Specifically, imbalances in microbial populations, such as an overgrowth of Demodex mites or harmful bacteria, can exacerbate symptoms. In vivo testing of skincare products for rosacea is essential to ensure that formulations are compatible with the unique microbiome of rosacea-prone skin. Such testing allows researchers to observe real-world effects on microbial balance and inflammation, ensuring that products do not unintentionally worsen symptoms. Without this careful testing, products may disrupt the microbiome further, leading to increased redness, irritation, or flare-ups. Sequential is leading the way in microbiome testing for the industry. With a specialized focus on skin conditions, we have developed an innovative solution tailored to help you understand the root causes of rosacea at the microbial level. Our proprietary sequencing panel is designed specifically to offer in-depth analysis of rosacea-associated microbiota, giving you the tools to transform skincare solutions. Customized Analysis Tailored insights specific to rosacea-prone skin, allowing your R&D team to develop more personalized and effective products. Actionable Data Leverage detailed reports to guide formulation decisions and validate product efficacy with precision. Product Innovation New rosacea treatments or enhancing existing lines, our data helps you create targeted solutions with proven results. Precision Sequencing Target specific microbial communities associated with rosacea development and severity. Smart Probe s ™ Our dedicated team of scientists has developed a revolutionary method for evaluating microbes through our Smart Probes™, a proprietary panel that includes 23 key microbes specifically identified as having the most significant impact on skin health. To further understand the complex relationship between rosacea and the skin microbiome, we utilize qPCR technology. This advanced method allows us to accurately quantify microbial populations on the skin, offering deeper insights into how rosacea affects the balance of beneficial and harmful microbes. By closely monitoring how skincare products interact with these microbes, companies can develop solutions that not only target rosacea symptoms but also help restore a healthier, balanced skin microbiome, providing long-term relief for sufferers. Rosacea Panel Targets Demodex mites (Demodex folliculorum and Demodex brevis) These tiny mites are normally present on the skin but are often found in higher numbers on the skin of individuals with rosacea. Their presence is thought to trigger inflammatory responses. Forton FMN. The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea? Dermatol Ther (Heidelb). 2020 Dec;10(6):1229-1253. doi: 10.1007/s13555-020-00458-9. Epub 2020 Oct 23. PMID: 33095403; PMCID: PMC7649190. Kim HS. Microbiota in Rosacea. Am J Clin Dermatol. 2020 Sep;21(Suppl 1):25-35. doi: 10.1007/s40257-020-00546-8. PMID: 32914214; PMCID: PMC7584533. Bacillus oleronius This bacterium has been linked to rosacea, particularly in relation to the inflammatory response associated with the condition. It is often found in higher quantities on the skin of rosacea patients. Corynebacterium kroppenstedtii This bacterium appears to be significantly overrepresented in papulopustular and mixed rosacea compared to healthy skin, with its presence correlating with disease severity and lesion spread, suggesting a potential opportunistic or contributory role in rosacea pathophysiology. Chien AL, Kang S, et al. Characterization and Analysis of the Skin Microbiota in Rosacea. J Am Acad Dermatol. 2020; PMID: 31502207. Industry Leader in Absolute Quantification Sequential’s Smart Probe ™ qPCR approach to microbiome analysis can resolve species and subspecies, giving statistically significant findings between skin conditions on in vivo human samples, compared to conventional sequencing approaches. Relevant Research How Does the Skin Microbiome Influence Rosacea? Unveiling the Microbial Puzzle Read More Articles

Taking a microbiome sample for the purpose of gene expression.

Genom and Sequential Announce Strategic Partnership to Advance Microbiome Testing Services in Personal Care and Pharma Sectors Zagreb, Croatia / London, UK – May 6 2025 – Genom d.o.o., a Croatian-based provider of genetic testing services, and Sequential Skin Ltd, a UK-based leader in end-to-end microbiome testing solutions, are pleased to announce a strategic partnership aimed at expanding access to advanced microbiome testing across the personal care and pharmaceutical industries. Through this agreement, Genom and Sequential are collaborating to expand microbiome testing efforts across the Balkans and Slavic regions—areas that have historically been underrepresented in microbiome research. By combining Genom’s deep regional expertise and network with Sequential’s advanced testing platform, the partnership aims to unlock valuable insights from a more diverse population base. This initiative supports both companies’ shared vision of advancing personalized health and product development through inclusive, data-driven innovation in the personal care and pharmaceutical industries. Sequential’s proprietary platform offers extensive sampling capabilities—including skin, scalp, oral, gut, and intimate areas—combined with advanced downstream analysis techniques such as qPCR and next-generation sequencing. With over a decade of academic research backing its methodology, Sequential empowers brands to better understand individual microbiomes and tailor products accordingly. Genom brings to the partnership a strong foundation in molecular biology and over a decade of experience in genetic testing, now expanding into microbiome analytics to support local companies in developing evidence-based products in the personal care and pharmaceutical sectors. Together with Sequential, Genom will play a key role in supporting regional operations, and scientific collaboration. This partnership is designed to jointly deliver tailored microbiome solutions to personal care and pharmaceutical companies. “Partnering with Genom allows us to explore the microbiome in regions that have been largely overlooked,” said Oliver Worsley, CEO of Sequential Skin Ltd . “It’s an exciting step toward building a richer, more representative microbiome dataset — one that will ultimately lead to better, more inclusive solutions in personal care and health.” “We are proud to be bringing world-class microbiome testing to our local industry. This partnership allows brands in our region to validate their innovations scientifically and competitively,” said Maja Barbalić, CEO of Genom d.o.o . About Genom d.o.o. Genom is a Croatian-based company specializing in molecular diagnostics and human genetics. Leveraging a scientific foundation and strategic industry connections, Genom supports its partners in bringing evidence-based innovations to market. About Sequential Skin Ltd Sequential is the world’s leading microbiome platform for skin, scalp and intimate area clinical microbiome testing. Sequential has collected over 25,000 microbiome samples, using machine learning to combine microbiome + clinical data + formulations, for effective personal care and healthcare applications. They are backed by Innovate UK Smart Grants, Enterprise Singapore, Corundum Systems Biology, SOSV, Scrum Ventures, and Metaplanet Holdings. Clients include Johnson & Johnson, Walgreens Boots Alliance, and 60 other leading clients in personal care and pharmaceutical.